GO
Loading...

Life Sciences

More

  • March 20- An experimental cancer vaccine from GlaxoSmithKline has failed in a second test- this time against lung cancer- but the British group said it still hoped to find a sub-group of patients in which it would work.

  • March 18- Shares of Galena Biopharma Inc fell as much as 21 percent on Tuesday after the company said the U.S. Securities and Exchange Commission was investigating its dealings with an external investor-relations firm.

  • Rivals race to develop new biotech asthma drugs Tuesday, 18 Mar 2014 | 8:48 AM ET

    *Rivals include Roche, AstraZeneca, Sanofi and Teva. LONDON, March 18- Rival firms are racing to develop injectable biotech asthma drugs for patients with severe disease who don't respond well to traditional inhalers, in pursuit of a new market worth a possible $7.5 billion.

  • March 14- An experimental Amgen Inc cancer vaccine used to treat advanced melanoma, the deadliest form of skin cancer, proved effective in a late-stage study in shrinking tumors in a way that suggests the drug triggered the intended systemic immune response, according to data presented on Friday.

  • March 10- Germany has granted Northwest Biotherapeutics Inc special permission to sell its experimental brain cancer drug in the country, the company said, and its stock jumped as much as 36 percent.

  • March 10- German health regulators have granted Northwest Biotherapeutics Inc special permission to sell its experimental brain cancer drug, DCVax-L, in the country, even though the small U.S. biotechnology company has not yet completed its late-stage trial of the immunotherapy.

  • Gene therapy may offer "functional" cure for HIV Wednesday, 5 Mar 2014 | 5:00 PM ET

    Data from the small study of the Sangamo BioSciences therapy, known by the code name SB-728-T, were issued in the New England Journal of Medicine, the first publication of data from a human trial of a technology called "gene editing." The Phase 1 trial, led by the University of Pennsylvania, enrolled 12 HIV patients.

  • Feb 19- Onconova Therapeutics Inc said its experimental blood disorder drug did not meet the main goal of a late-stage trial, sending its shares down 45 percent in extended trading. Since then the company's shares have fallen a little more than 15 percent and closed at $13.86 on Wednesday. The stock was trading at $8.35 in extended trading.

  • Feb 4- The U.S. Food and Drug Administration rejected a migraine drug made by Israel's RedHill Biopharma Ltd and Canada's IntelGenx Corp.. The FDA raised questions about the third-party manufacturing process, as well as the packaging and labeling of the drug, called RHB-103, the companies said in a statement.

  • *Ablynx initially to get 20 mln euros, plus 10.7 mln for research. *Ablynx shares gain up to 6.9 pct. BRUSSELS, Feb 3- Belgian biotech company Ablynx has signed a deal with Merck& Co worth up to 1.7 billion euros to develop ways of triggering the body to fight cancer by itself.

  • *Follows quality issue with some batches made in Belgium. FRANKFURT/ LONDON, Jan 28- GlaxoSmithKline has stopped worldwide deliveries of two chickenpox vaccines for children after discovering that some batches produced at its factory in Wavre, Belgium, were not up to standard.

  • Ancient master goldsmiths were master crooks, too Friday, 26 Jul 2013 | 2:44 PM ET
    Metal workers from the time of ancient Rome were experts at shiny finishes.

    Metal workers 2,000 years ago perfected plating techniques that modern methods can't touch. Some probably coated cheap metal or wood objects in a gilded skin and sold them for big profits. NBC reports.

  • More Women Choosing Preventive Mastectomies Tuesday, 14 May 2013 | 3:34 PM ET
    Angelina Jolie

    The number of women choosing to have preventive mastectomies has risen by almost 50 percent in recent years, and surveys show they are happy with the decision.

  • Public Doubt on Bird Flu a Ghost of China's Past Tuesday, 9 Apr 2013 | 10:26 PM ET

    China has earned praise from international scientists for its handling of an outbreak of a deadly new bird flu, but a history of public health cover-ups means the Chinese public is harder to win over.

  • China's Bird Flu Outbreak Not Cause for Panic: WHO Monday, 8 Apr 2013 | 4:57 AM ET

    A strain of bird flu that has been found in humans for the first time in eastern China is not a cause for panic, the World Health Organization said on Monday, even as the number of people infected rose to 21, with six deaths.

  • CNBC's Jon Fortt speaks with Facebook founder & CEO Mark Zuckerberg and Apple Chairman Art Levinson about a new foundation to offer a $33 million prize for life science research. "We all think our society needs more heroes who are scientists, researchers and engineers," he says.

  • With Group Effort, Japan Suicides Fall to 15-Year Low Wednesday, 23 Jan 2013 | 7:56 PM ET

    Japan has one of the world’s highest suicide rates. But last year the number of suicides fell below 30,000 for the first time in 15 years, thanks in part to community efforts. The CSM reports.

  • Eli Lilly will be "very challenged" by the loss of exclusivity on several blockbuster drugs, CEO John Lechleiter told CNBC on Tuesday, but added the company can manage its growth in response.

  • E.T. Tweet Home Wednesday, 27 Jun 2012 | 11:09 AM ET

    The National Geographic Channel is preparing to beam tweets into space, in response to the "Wow! signal," a transmission received from space.

  • DNA Sequencing Caught in Deluge of Data Thursday, 1 Dec 2011 | 12:51 PM ET

    BGI, based in China, is the world’s largest genomics research institute, with 167 DNA sequencers producing the equivalent of 2,000 human genomes a day, the New York Times reports.